Reduction in abdominal symptoms (CFAbd-Score), faecal M2-pyruvate-kinase and Calprotectin over one year of treatment with Elexacaftor-Tezacaftor-Ivacaftor in people with CF aged ≥12 years – The RECOVER study
Jochen G. Mainz, Karen Lester, B. Elnazir, Michael Williamson, E. McKone, D. Cox, Barry Linnane, Carlos Zagoya, Franziska Duckstein, Anton Barucha, Jane C. Davies, Paul McNally
Topics & Concepts
IvacaftorMedicineCystic fibrosisCalprotectinInternal medicineGastroenterologyCystic fibrosis transmembrane conductance regulatorDiseaseInflammatory bowel diseaseCystic Fibrosis Research AdvancesRespiratory and Cough-Related ResearchGastroesophageal reflux and treatments